Evotec, Novo Nordisk
Evotec and Novo Nordisk in technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec SE (NASDAQ:EVO) entered a technology development partnership with Novo Nordisk A/S (NYSE:NVO) in cell therapy. Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline
While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26,
Evotec and Novo Nordisk team up on cell therapies
Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo Nordisk will fund R&D at Evotec’s sites in Germany and Italy, with an option for exclusive rights to use the results in a specific therapeutic area.
Novo Nordisk expands stem cell research arm with Evotec
Evotec has joined forces with Novo Nordisk to advance the clinical and commercial manufacturing of stem cell-based therapies.
Evotec enters technology development partnership with Novo Nordisk in cell therapy
Evotec SE, a life science company, has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Evotec and Novo Nordisk forge technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
Evotec SE: Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / Septembe ...
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.